Institute for Myeloma

The Institute for Myeloma and Bone Cancer Research (IMBCR) is a premier independent non-profit research organization dedicated to the advancement of treatments for multiple myeloma and other bone-related cancers. Founded in 2003 by Dr. James Berenson, the institute specializes in translational research, effectively moving laboratory discoveries into clinical practice. IMBCR conducts a wide range of clinical trials, focusing on novel combination therapies and the identification of new therapeutic targets such as JAK and HDAC. By collaborating with major pharmaceutical companies and academic institutions, the institute aims to develop more effective and less toxic treatment options for patients. Their work is characterized by a commitment to personalized medicine and improving the long-term survival and quality of life for those affected by plasma cell malignancies.